Market capitalization | $8.47m |
Enterprise Value | $5.00m |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.82 |
Free Cash Flow (TTM) Free Cash Flow | $-16.00m |
Cash position | $3.47m |
P/E forward | negative |
Short interest | 10.62% |
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
1 Analyst has issued a forecast Genprex, Inc.:
1 Analyst has issued a forecast Genprex, Inc.:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -21 -21 |
32%
32%
|
EBIT (Operating Income) EBIT | -21 -21 |
32%
32%
|
Net Profit | -21 -21 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Head office | United States |
CEO | Ryan Confer |
Employees | 15 |
Founded | 2009 |
Website | www.genprex.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.